This is a working overview of WADA Prohibited List, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-06 and is reviewed periodically as new material appears.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
=== Canada === In 2002, Health Canada issued an order prohibiting the sale of any product containing kava. While the restrictions on kava were lifted in 2012, Health Canada lists five kava ingredients, as of 2017, and manufactured products containing kava or its extracts must be approved by the federal government before marketing.
=== Legal status === Datopotamab deruxtecan was approved for medical use in the United States in January 2025. In December 2024, the US Food and Drug Administration granted the application for datopotamab deruxtecan breakthrough therapy designation. In January 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Datroway, intended for the treatment of breast cancer. The applicant for this medicinal product is Daiichi Sankyo Europe GmbH. Datopotamab deruxtecan was authorized for medical use in the European Union in April 2025.
In each department, in each province of Peru occupied by the Colombians, small dictators exercised their functions, widely empowered to fleece the people (...) Prototype of those little dictators who in 1824 sowed terror in Peru, is that Manterola appointed governor of Huamachuco by Bolívar, who carried out his functions accompanied by his mistress, and at the same time that he looted the unfortunate towns of his jurisdiction and tortured his neighbors." Bolívar was also accused of carrying out a geopolitics with a clear anti-Peruvian direction in Gran Colombia, with absolute opposition to the interests of said political society, both in its form of the Viceroyalty of Peru and of the Republic of Peru, denouncing a mixture of admiration and envy of Peru's economic privileges, as well as suspicion for its population, which he constantly described as contemptuous, even before intervening in its political affairs, since this antipathy would have been clearly distilled since the years of the famous Jamaica Letter. (…) The Viceroyalty of Peru, whose population amounts to a million and a half inhabitants, is undoubtedly the most submissive and from which the most sacrifices have been made for the king's cause, (…) Chile can be free. Peru, on the contrary, contains two enemy elements of every fair and liberal nature: gold and slaves [referring to the Indians]. The first corrupts everything; the second is corrupted by itself. The soul of a servant [referring to the common people of Peru] rarely manages to appreciate healthy freedom; he rages in riots or humbles himself in chains.
== Nursing School == Affiliated to the hospital is a nursing school which graduated 295 students since 1998 up to 2001 with an average of 26 students per year to fulfill the needs of the Institute, the Ministry of health and other health organizations. In 2021, the Immunology and Therapeutic Evaluation Division at Institute was designated as a WHO Collaborating Center for Schistosomiasis Control for 3 years.
Sources: en.wikipedia.org
=== Regulation === The early 20th century brought increased regulation of all manner of narcotics, including paregoric, as the addictive properties of opium became more widely understood, and "patent medicines came under fire largely because of their mysterious compositions". In the United States, the Pure Food and Drug Act of 1906 required that certain specified drugs, including alcohol, cocaine, heroin, morphine, and cannabis, be accurately labeled with contents and dosage. Previously many drugs had been sold as patent medicines with secret ingredients or misleading labels. Cocaine, heroin, cannabis, and other such drugs continued to be legally available without prescription as long as they were labeled. It is estimated that sale of patent medicines containing opiates decreased by 33% after labeling was mandated. In 1906 in Britain and in 1908 in Canada laws requiring disclosure of ingredients and limitation of narcotic content were instituted. The U.S. Harrison Narcotics Tax Act of 1914 restricted the manufacture and distribution of opiates, including laudanum and coca derivatives; this was followed by France's Loi des stupefiants in 1916 and Britain's Dangerous Drugs Act in 1920. The Harrison Narcotics Tax Act regulated "opium or coca leaves, or any compound, manufacture, salt, derivative or preparation thereof", but not some medical products containing relatively low concentrations of these substances. Paregoric was classified as an "Exempt Narcotic", as were other medical products containing small amounts of opium or their derivatives.
Cardiovascular: low blood pressure, high blood pressure, swelling Central nervous system: insomnia Dermatological: rash Gastrointestinal: diarrhea, abdominal pain Hematological: eosinophilia Respiratory: dyspnea Other: injection site reactions, fever, hypersensitivity Less common, but serious adverse events reported in the literature include
=== Molecular representations for chirality === Computational methods for representing molecular chirality must encode three-dimensional stereochemical information in a format suitable for machine learning algorithms. SMILES (Simplified Molecular Input Line Entry System) notation incorporates stereochemistry through the use of @ and @@ symbols at chiral centers, where @ typically denotes anticlockwise and @@ denotes clockwise configuration when viewing the chiral center along the bond from the center to the first atom in the SMILES string. Traditional molecular descriptors used in computational chemistry, such as circular fingerprints (Extended Connectivity Fingerprints or ECFP), can encode structural information including stereochemical features. These descriptors represent molecules as fixed-length binary vectors that capture local atomic environments and connectivity patterns. However, conventional fingerprints may not optimally capture the subtle three-dimensional differences between enantiomers. Neural network-based molecular representations can be derived from SMILES strings. Variational autoencoders and heteroencoders trained on large databases of molecular structures can generate latent space vectors (LSVs) that encode molecular properties in a continuous, lower-dimensional space. These methods calculate difference vectors between the descriptor of a molecule and that of its enantiomer, or between the original descriptor and one derived from a stereochemistry-depleted SMILES string.
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.